Otsuka Company Analysis
Otsuka Company Analysis
$3,000.00
PharmaVitae explores Otsuka’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
PharmaVitae explores Otsuka’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.
Snapshot
- 2021 outlook – Otsuka’s CNS franchise will return the company to growth in 2017, following the loss of patent exclusivity of Abilify in the US in April 2015.
- 2026 outlook – Topline will grow by $3.9bn as CNS and oncology portfolios expand.
- Events – Lifecycle management strategies help combat eroding Abilify sales; Rexulti growth is hindered by mixed Phase III efficacy data; Discontinuation of Idalopirdine, Sativex, and SGI-110 programs.
Highlights
- Otsuka will successfully mitigate the genericization of flagship product Abilify, and will increase sales at a CAGR of 4.6%.
- Otsuka will add $3.2bn in sales within its CNS portfolio, primarily from products acquired through Avanir Pharmaceuticals and from a collaboration agreement with Lundbeck,
- Lonsurf and SGI-110 will be Otsuka’s main growth drivers in the oncology portfolio.
Model Updates
- Vadadustat added.
- Revised Rexulti in anxiety associated with Alzheimer’s disease.
- Discontinuation of Idalopirdine.
- Discontinuation of SGI-110 in hepatocellular carcinoma.
- Discontinuation of Sativex in cancer pai n.
Analysis structure
Company context
- How is Otsuka strategically poised out to 2026?
- What are Otsuka’s key strengths, weaknesses, opportunities and threats?
- What are Otsuka’s key catalysts over the next four quarters?
Facts and figures
- What is Otsuka’s forecasted sales performance out to 2026?
- What is the revenue trajectory of Otsuka’s current top 10 products out to 2026?
- Which therapy areas will experience the largest growth and decline?
- What are the portfolio weightings of Otsuka based on the lifecycle of products?
Key Therapy Areas
- Why will specific therapy areas will experience the largest growth and decline?
- What are the detailed competitive dynamics at play in Otsuka’s important therapeutic markets?
- How is Otsuka adapting to strategically to internal and external headwinds?
CONTENTS
5 EXECUTIVE SUMMARY
6 COMPANY CONTEXT
6 Company Structure
6 Transitional period for Otsuka
6 Growth Drivers
6 Vadadustat in-licensing deal
7 Otsuka’s SWOT Analysis
8 Otsuka’s key events and catalysts
10 FACTS AND FIGURES
10 Otsuka’s prescription pharma sales outlook
10 Otsuka’s therapy area dynamics
14 Otsuka’s top 10 products over 2016–26
14 Otsuka’s growth drivers and resistors
19 Otsuka’s launch/core/expiry analysis
22 Otsuka’s financial outlook
23 Otsuka’s M&A history
25 KEY THERAPY AREAS
25 Central nervous system
31 Oncology
39 BIBLIOGRAPHY
LIST OF FIGURES
10 Figure 1: Otsuka’s prescription pharmaceutical sales ($m) and growth rate (%), 2013–26
11 Figure 2: Otsuka’s therapy area dynamics, 2016–26
14 Figure 3: Otsuka’s top 10 product sales ($m), 2016–26
20 Figure 4: Otsuka’s launch/core/expiry analysis, 2016–26
22 Figure 5: Otsuka’s operating revenue/cost analysis ($m), 2010–22
LIST OF TABLES
12 Table 1: Otsuka’s sales by therapy area ($m), 2016–26
15 Table 2: Otsuka’s key products, 2016–26
21 Table 3: Otsuka’s sales by launch, core, and expiry portfolio ($m), 2016–26
23 Table 4: Otsuka’s financial performance, 2016–22
24 Table 5: Otsuka’s key merger and acquisition deals, 2003–17
26 Table 6: Otsuka’s central nervous system portfolio ($m), 2016–26
30 Table 7: Products acquired from Avanir Pharmaceuticals
33 Table 8: Otsuka’s oncology portfolio ($m), 2016–26
36 Table 9: Astex products and pipeline candidates
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Shionogi Company Analysis 
Sign up to the